Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Algorae PharmaceuticalsASX:1AI +4.00% 3-Year Share Buyback Ratio is -9.00 as of Dec. 2025. The stock has 2 warning signs investors should review. Among 1,195 Biotechnology companies, Algorae Pharmaceuticals ranks better than 55.15% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Algorae Pharmaceuticals's current 3-Year Share Buyback Ratio was -9.00%.
The historical rank and industry rank for Algorae Pharmaceuticals's 3-Year Share Buyback Ratio or its related term are showing as below:
ASX:1AI'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -46.4 Med: -11.7 Max: 0
Current: -9
During the past 13 years, Algorae Pharmaceuticals's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -46.40%. And the median was -11.70%.
ASX:1AI's 3-Year Share Buyback Ratio is ranked better than 55.15% of 1195
companies
in the Biotechnology industry
Industry Median: -11.7
vs ASX:1AI: -9.00
Algorae Pharmaceuticals (ASX:1AI) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Algorae Pharmaceuticals 3-Year Share Buyback Ratio Related Terms
ASX:1AI vs VRTX, REGN, ALNY: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Algorae Pharmaceuticals's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Algorae Pharmaceuticals 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Algorae Pharmaceuticals's 3-Year Share Buyback Ratio falls into.
Algorae Pharmaceuticals 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -9.00 mean?
Algorae Pharmaceuticals (ASX:1AI) has a 3-Year Share Buyback Ratio of -9.00 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Algorae Pharmaceuticals and its competitors. According to the industry distribution chart, Algorae Pharmaceuticals ranks #536 out of 1195 companies in the Biotechnology industry, placing it in the top 44.9%.
Is Algorae Pharmaceuticals' 3-Year Share Buyback Ratio too high?
Algorae Pharmaceuticals' current 3-Year Share Buyback Ratio is -9.00. Based on the distribution chart, Algorae Pharmaceuticals ranks #536 out of 1195 companies in the Biotechnology industry, which is above the industry midpoint.
How does Algorae Pharmaceuticals' 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Algorae Pharmaceuticals ranks #536 out of 1195 companies for 3-Year Share Buyback Ratio. This puts Algorae Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Algorae Pharmaceuticals and its competitors. Algorae Pharmaceuticals's current 3-Year Share Buyback Ratio is -9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Algorae Pharmaceuticals stock overvalued right now?
Algorae Pharmaceuticals (ASX:1AI) has a current 3-Year Share Buyback Ratio of -9.00. The current 3-Year Share Buyback Ratio is -9.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Algorae Pharmaceuticals (ASX:1AI), the current 3-Year Share Buyback Ratio is -9.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:1AI has been successfully added to your 
